ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022 DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

Collaborative work behind the scenes makes cancer breakthroughs possible

When we talk about breakthroughs in cancer research, most focus on the moment of discovery: a new therapy, a promising trial result, or a headline-grabbing study.

May 08, 2026

Vol.52 No.18

By Annaliese Daniels

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Brandeis University has announced that Sheila Efron Taube ’63, a pioneer in cancer research, will receive the Alumni Achievement Award for outstanding contributions to their fields and society.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

The Alliance for Clinical Trials in Oncology is enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.

April 17, 2026

Vol.52 No.15

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

Clinical Roundup

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022

DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer

YOU MAY BE INTERESTED IN

Collaborative work behind the scenes makes cancer breakthroughs possible

FDA adds stereotactic breast biopsy needles to the shortage list

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Renew today!

Subscriber content

Never miss an issue!

Login